Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) (AUGMENT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Celgene Corporation
Information provided by (Responsible Party):
Celgene Corporation Identifier:
First received: September 5, 2013
Last updated: October 15, 2014
Last verified: October 2014

This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab (MabThera/Rituxan) in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma. Patients will be randomized to receive either lenalidomide or placebo for twelve 28-day cycles in combination with rituximab. Anticipated time on study treatment is 1 year.

Condition Intervention Phase
Lymphoma, Non-Hodgkin
Drug: Rituximab
Drug: Lenalidomide
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma (The "AUGMENT" Study)

Resource links provided by NLM:

Further study details as provided by Celgene Corporation:

Primary Outcome Measures:
  • Progression free survival (PFS) for indolent lymphoma (Follicular lymphoma and Marginal zone lymphoma [ Time Frame: Up to 8 years ] [ Designated as safety issue: No ]
    Progression-free survival is defined as the time from date of randomization to the first observation of disease progression or death due to any cause as assessed by an independent review committee.

Secondary Outcome Measures:
  • Overall response rate for indolent lymphoma (Follicular lymphoma and Marginal zone lymphoma) [ Time Frame: Up to 8 years ] [ Designated as safety issue: No ]
    Overall response rate is defined as proportion of subjects with best response of at least partial remission during the trial without administration of new anti-lymphoma therapy.

  • Durable complete response rate for indolent lymphoma (Follicular lymphoma and Marginal zone lymphoma) [ Time Frame: Up to 8 years ] [ Designated as safety issue: No ]
    Rate of durable complete response defined as complete response of at least 1 year's duration

  • Overall survival for indolent lymphoma (Follicular lymphoma and Marginal zone lymphoma) [ Time Frame: Up to 8 years ] [ Designated as safety issue: No ]
    Overall survival is defined as time from date of randomization to death from any cause

  • Duration of response for indolent lymphoma (Follicular lymphoma and Marginal Zone lymphoma) [ Time Frame: Up to 8 years ] [ Designated as safety issue: No ]
    Duration of response is defined as time from initial response of at least a PR to documented progression/relapse

  • Event Free Survival for indolent lymphoma (Follicular lymphoma and Marginal Zone lymphoma) [ Time Frame: Up to 8 years ] [ Designated as safety issue: No ]
    Event-free survival is defined as the time from the date of randomization to the first observation of disease progression, institution of new anti-lymphoma treatment, or death due to any cause

  • Time to next anti-lymphoma therapy (TTNLT) for indolent lymphoma (Follicular lymphoma and Marginal Zone lymphoma) [ Time Frame: Up to 8 years ] [ Designated as safety issue: No ]
    TTNLT is defined as the time from date of randomization to institution of new anti-lymphoma treatment

  • Safety in indolent lymphoma (Follicular lymphoma and Marginal Zone lymphoma) [ Time Frame: Up to 8 years ] [ Designated as safety issue: Yes ]
    Incidence of Adverse Events (AEs). An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an AE.

Estimated Enrollment: 350
Study Start Date: September 2013
Estimated Study Completion Date: December 2021
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rituximab and Lenalidomide Drug: Rituximab
Rituximab 375mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
Other Name: Rituxan
Drug: Lenalidomide
Lenalidomide 20mg by mouth (PO) QD on Days 1 to 21 every 28 days up to 12 cycles
Other Name: CC-5013, Revlimid
Active Comparator: Rituximab and Placebo Drug: Rituximab
Rituximab 375mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
Other Name: Rituxan
Drug: Placebo
Placebo (identical matched capsule) PO QD Days 1 to 21 every 28 days

Detailed Description:

Indolent lymphoma is a slow growing but incurable lymphoma which includes follicular lymphoma and marginal zone lymphoma. Follicular Lymphoma and Marginal zone lymphoma are cancers of the B lymphocyte, a type of white blood cell. Lenalidomide is an immunomodulatory drug (a drug that affects the immune system) which alters the body's immune system and it may also interfere with the development of tiny blood vessels involved in tumor growth. Therefore, lenalidomide may reduce or prevent the growth of cancer cells. Lenalidomide has also been shown to restore the immune cells' ability to attack and kill tumor cells, an ability that may be inhibited by follicular lymphoma and other lymphomas. The combination of rituximab and lenalidomide may eliminate the cancer while restoring the immune system's ability to attack tumor cells.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥18 years

    • Histologically confirmed marginal zone lymphoma or follicular lymphoma (grade 1, 2 or 3a)
    • Documented relapsed, refractory or progressive disease after treatment with systemic therapy
    • Rituximab naïve or rituximab sensitive
    • Investigator considers rituximab monotherapy appropriate
    • Bi-dimensionally measurable disease
    • Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2
    • Adequate bone marrow function
    • Willingness to follow pregnancy precautions

Exclusion Criteria:

  • Histology other than follicular or marginal zone lymphoma or clinical evidence of transformation or Grade 3b follicular lymphoma

    • Subjects taking corticosteroids during the last week, unless administered at a dose equivalent to < 20 mg/day prednisone or prednisolone
    • Systemic anti-lymphoma therapy within 28 days or use of antibody agents within 8 weeks use of radioimmunotherapy within 6 months
    • Known seropositive for or active viral infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV)
    • Known sensitivity or allergy to murine products
    • Presence or history of central nervous system involvement by lymphoma.
    • Subjects who are at a risk for a thromboembolic event and are not willing to take prophylaxis for it.
    • Any condition that places the subject at unacceptable risk if he/she were to participate in the study or that confounds the ability to interpret data from the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01938001

Contact: Emmanual Ryembault, MS Neuropsychopharmacology
Contact: Kenichi Takeshita, MD

  Show 111 Study Locations
Sponsors and Collaborators
Celgene Corporation
Study Director: Barbara Amoroso, MD Celgene Corporation
  More Information

No publications provided

Responsible Party: Celgene Corporation Identifier: NCT01938001     History of Changes
Other Study ID Numbers: CC-5013-NHL-007
Study First Received: September 5, 2013
Last Updated: October 15, 2014
Health Authority: United States: Food and Drug Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Czech Republic: State Institute for Drug Control
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Germany: Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)
Italy: Agenzia Italiana del Farmaco
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Portugal: INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde IP Direcção de Avaliação de Medicamentos Parque da Saúde de Lisboa
Spain: Agencia Española de Medicamentos y Productos Sanitarios
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Israel: Israeli Health Ministry Pharmaceutical Administration
Russia: Ministry of Healthcare of the Russian Federation
Brazil: Agência Nacional de Vigilância Sanitária (ANVISA)
Turkey: T.R.Ministry of Health, Turkish Drug&Medical Device Agency, Drug, Biologic&Medical Products Presidency,
China: Food and Drug Administration
Japan: Pharmaceuticals and Medical Devices Agency

Keywords provided by Celgene Corporation:
Non-Hodgkins Follicular lymphoma, Non-Hodgkins Marginal zone lymphoma, treatment for follicular lymphoma, treatment for Marginal zone lymphoma

Additional relevant MeSH terms:
Lymphoma, B-Cell, Marginal Zone
Lymphoma, Follicular
Lymphoma, Non-Hodgkin
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, B-Cell
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Antirheumatic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 20, 2014